The mutant IDH1 inhibitors ivosidenib [61, 62] and olutasidenib [63] and the mutant IDH2 inhibitor enasidenib [64, 65] relieve this differentiation block and are approved by the FDA as single agents for the treatment of IDH1mut and IDH2mut AML, respectively. Here, IDH2 is linked to acute myeloid leukemia.